...
首页> 外文期刊>PLoS Genetics >Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease
【24h】

Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease

机译:临床诊断为阿尔茨海默病的神经变性孟德尔基因分析

获取原文
           

摘要

Alzheimer disease (AD), Frontotemporal lobar degeneration (FTD), Amyotrophic lateral sclerosis (ALS) and Parkinson disease (PD) have a certain degree of clinical, pathological and molecular overlap. Previous studies indicate that causative mutations in AD and FTD/ALS genes can be found in clinical familial AD. We examined the presence of causative and low frequency coding variants in the AD, FTD, ALS and PD Mendelian genes, in over 450 families with clinical history of AD and over 11,710 sporadic cases and cognitive normal participants from North America. Known pathogenic mutations were found in 1.05% of the sporadic cases, in 0.69% of the cognitively normal participants and in 4.22% of the families. A trend towards enrichment, albeit non-significant, was observed for most AD, FTD and PD genes. Only PSEN1 and PINK1 showed consistent association with AD cases when we used ExAC as the control population. These results suggest that current study designs may contain heterogeneity and contamination of the control population, and that current statistical methods for the discovery of novel genes with real pathogenic variants in complex late onset diseases may be inadequate or underpowered to identify genes carrying pathogenic mutations. Author summary In this study we provide further genetic evidence of the clinical, pathological and molecular overlap between neurodegenerative diseases. We screened the known Mendelian genes in Alzheimer disease (AD), Frontotemporal Dementia (FTD), Parkinson disease (PD) and Amyotrophic Lateral Sclerosis (ALS) disease in over 13,292 individuals. We report the presence of known pathogenic mutations in AD, FTD and PD genes in both sporadic and familial late onset AD cases and even cognitively normal individuals, pointing to contamination of control cohorts with asymptomatic cases. We also observed an enrichment, although not statistically significant, in most of AD, FTD and PD genes, reinforcing the idea of pathologic crossover among these diseases. However, the fact that genes carrying known pathogenic mutation do not show significant association calls for a reevaluation of current statistical methods.
机译:阿尔茨海默病(AD),额颞叶变性(FTD),肌萎缩性侧索硬化症(ALS)和帕金森氏病(PD)在临床,病理和分子上都有一定程度的重叠。先前的研究表明,AD和FTD / ALS基因的致病性突变可在临床家族性AD中发现。我们检查了超过450个具有AD临床病史的家庭以及超过11,710个散发病例和来自北美的认知正常参与者的AD,FTD,ALS和PD孟德尔基因中的致病性和低频编码变异体的存在。在1.05%的散发病例,0.69%的认知正常参与者和4.22%的家庭中发现了已知的致病突变。对于大多数AD,FTD和PD基因,观察到了富集趋势,尽管不显着。当我们使用ExAC作为对照人群时,只有PSEN1和PINK1与AD病例显示出一致的关联。这些结果表明,当前的研究设计可能包含对照人群的异质性和污染,并且当前用于发现复杂迟发性疾病中具有真实致病变异的新基因的统计方法可能不足或不足以鉴定携带致病突变的基因。作者摘要在这项研究中,我们提供了神经退行性疾病之间临床,病理和分子重叠的进一步遗传证据。我们在超过13,292个人中筛选了阿尔茨海默氏病(AD),额颞痴呆(FTD),帕金森氏病(PD)和肌萎缩性侧索硬化症(ALS)疾病的已知孟德尔基因。我们报告了散发和家族性晚发型AD病例甚至认知正常个体中AD,FTD和PD基因中已知的致病突变,这表明对照组无症状病例受到污染。我们还观察到大多数AD,FTD和PD基因的富集,尽管在统计学上不显着,但加强了这些疾病之间病理交叉的观念。但是,携带已知致病突变的基因没有显示出显着的关联性,这要求重新评估当前的统计方法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号